Huber Capital Management LLC Astrazeneca PLC Transaction History

Huber Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$54.02 - $63.83 $184,262 - $217,724	-3,411 Reduced 97.46%	89 $5,000
Q3 2021 Nov 12, 2021	SELL	$55.56 - $60.79 $66,672 - $72,948	-1,200 Reduced 25.53%	3,500 $210,000
Q1 2021 May 14, 2021	SELL	$47.16 - $54.44 $70,740 - $81,660	-1,500 Reduced 24.19%	4,700 $234,000
Q4 2020 Feb 12, 2021	SELL	$48.52 - $58.02 $116,448 - $139,248	-2,400 Reduced 27.91%	6,200 $310,000
Q1 2020 May 14, 2020	BUY	$37.79 - $51.33 $18,895 - $25,665	500 Added 6.17%	8,600 $384,000
Q4 2019 Feb 13, 2020	SELL	$42.46 - $50.46 $127,380 - $151,380	-3,000 Reduced 27.03%	8,100 $404,000
Q1 2019 May 14, 2019	SELL	$35.49 - $43.02 $1.52 Million - $1.84 Million	-42,800 Reduced 79.41%	11,100 $449,000
Q3 2018 Nov 13, 2018	BUY	$34.76 - $39.72 $917,664 - $1.05 Million	26,400 Added 96.0%	53,900 $2.13 Million
Q3 2017 Nov 13, 2017	BUY	$28.96 - $34.0 $796,400 - $935,000	27,500	27,500 $932,000

1,358

512M

6.08M

4.44M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $234B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Huber Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Huber Capital Management LLC with notifications on news.